Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 6/20 | 0.86 |
| ▸ | GMNN | O75496 | 1/20 | 0.86 |
| ▸ | LMNA | P02545 | 1/20 | 0.86 |
| ▸ | POLB | P06746 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | BLM | P54132 | 1/20 | 0.86 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22345172 | 1.00 | TSPO (0.86) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL30849696 | 1.00 | TSPO (0.86) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL30849701 | 1.00 | TSPO (0.86) | TSPOGMNNLMNAPOLBCYP3A4 | |
| Alpdem SCHEMBL1230701 | 0.93 | TSPO (1.00) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL22627637 | 0.92 | TSPO (0.73) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL22627545 | 0.92 | TSPO (0.90) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL21191657 | 0.90 | TSPO (0.86) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL27218941 | 0.88 | TSPO (0.80) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL22612467 | 0.88 | TSPO (0.83) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL21191506 | 0.88 | TSPO (0.83) | TSPOGMNNLMNAPOLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156997-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2024-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156997-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | TSPO, FABP7, SLC46A1 | TSPO 1/4885GMNN 3686/4885LMNA 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.